CHT101

DRUG4 trials

Sponsors

Zhejiang University, Tianjin Medical University Cancer Institute and Hospital, Nanjing Miracle Biotechnology Co., Ltd.

Conditions

Advanced Solid TumorCervix CancerCutaneous T-cell Lymphoma (CTCL)Head and Neck Squamous Cell CarcinomaHematological MalignanciesMetastatic TumorNHL (Non-Hodgkin Lymphoma)Nasopharyngeal Carcinoma

Phase 1

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Not yet recruitingNCT06383507

Zhejiang UniversityAdvanced Solid Tumor, Cervix Cancer, Head and Neck Squamous Cell Carcinoma +4

Start: 2024-04-22End: 2029-04-21Target: 18Updated: 2024-04-25

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors

RecruitingNCT06730659

Tianjin Medical University Cancer Institute and HospitalRelapsed / Refractory Solid Tumor

Start: 2024-04-19End: 2039-04-18Target: 36Updated: 2024-12-12

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

RecruitingNCT06914037

Tianjin Medical University Cancer Institute and HospitalCutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma), Peripheral T-cell Lymphoma

Start: 2025-03-31End: 2028-03-31Target: 24Updated: 2025-04-06

A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies

Not yet recruitingNCT07809139

Nanjing Miracle Biotechnology Co., Ltd.Hematological Malignancies

Start: 2026-09-01End: 2028-12-01Target: 30Updated: 2026-09-09